Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19
Abstract Background Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed.Methods 2,335 patients who received single-dose bamlanivimab infusion between November 12, 2020 to February 17, 2021 were compared with a propensity-matched control of 2,335 untreated patients with mild to moderate COVID-19 at Mayo Clinic facilities across 4 states. The primary outcome was the rate of hospitalization at days 14, 21 and 28.Results The median age of the population was 63; 47.3% of the bamlanivimab-treated cohort were ≥65 years; 49.3% were female. High-risk characteristics included hypertension (54.2%), body mass index ≥35 (32.4%), diabetes mellitus (26.5%), chronic lung disease (25.1%), malignancy (16.6%), and renal disease (14.5%). Patients who received bamlanivimab had lower all-cause hospitalization rates at days 14 (1.5% vs 3.5%; Odds Ratio [OR], 0.38), 21 (1.9% vs 3.9%; OR, 0.46), and 28 (2.5% vs 3.9%; OR, 0.61). Secondary exploratory outcomes included lower intensive care unit admission rates at days 14 (0.14% vs 1%; OR, 0.12), 21 (0.25% vs 1%; OR: 0.24) and 28 (0.56% vs 1.1%; OR: 0.52), and lower all-cause mortality at days 14 (0% vs 0.33%), 21 (0.05% vs 0.4%; OR,0.08) and 28 (0.11% vs 0.44%; OR, 0.01). Adverse events were uncommon with bamlanivimab, occurring in 19/2355, most commonly fever (n=6), nausea (n=5), and lightheadedness (n=3).Conclusions Among high-risk patients with mild to moderate COVID-19, treatment with bamlanivimab was associated with a statistically significant lower rate of hospitalization compared with usual care.Funding Mayo Clinic..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 28. Dez. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ganesh, Ravindra [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.05.23.21257670 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI020629311 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI020629311 | ||
| 003 | DE-627 | ||
| 005 | 20230429092500.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210527s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.05.23.21257670 |2 doi | |
| 035 | |a (DE-627)XBI020629311 | ||
| 035 | |a (biorXiv)10.1101/2021.05.23.21257670 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ganesh, Ravindra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed.Methods 2,335 patients who received single-dose bamlanivimab infusion between November 12, 2020 to February 17, 2021 were compared with a propensity-matched control of 2,335 untreated patients with mild to moderate COVID-19 at Mayo Clinic facilities across 4 states. The primary outcome was the rate of hospitalization at days 14, 21 and 28.Results The median age of the population was 63; 47.3% of the bamlanivimab-treated cohort were ≥65 years; 49.3% were female. High-risk characteristics included hypertension (54.2%), body mass index ≥35 (32.4%), diabetes mellitus (26.5%), chronic lung disease (25.1%), malignancy (16.6%), and renal disease (14.5%). Patients who received bamlanivimab had lower all-cause hospitalization rates at days 14 (1.5% vs 3.5%; Odds Ratio [OR], 0.38), 21 (1.9% vs 3.9%; OR, 0.46), and 28 (2.5% vs 3.9%; OR, 0.61). Secondary exploratory outcomes included lower intensive care unit admission rates at days 14 (0.14% vs 1%; OR, 0.12), 21 (0.25% vs 1%; OR: 0.24) and 28 (0.56% vs 1.1%; OR: 0.52), and lower all-cause mortality at days 14 (0% vs 0.33%), 21 (0.05% vs 0.4%; OR,0.08) and 28 (0.11% vs 0.44%; OR, 0.01). Adverse events were uncommon with bamlanivimab, occurring in 19/2355, most commonly fever (n=6), nausea (n=5), and lightheadedness (n=3).Conclusions Among high-risk patients with mild to moderate COVID-19, treatment with bamlanivimab was associated with a statistically significant lower rate of hospitalization compared with usual care.Funding Mayo Clinic. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Pawlowski, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a O’Horo, John C. |e verfasserin |4 aut | |
| 700 | 1 | |a Arndt, Lori L. |e verfasserin |4 aut | |
| 700 | 1 | |a Arndt, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, Sarah J. |e verfasserin |4 aut | |
| 700 | 1 | |a Bierle, Dennis M. |e verfasserin |4 aut | |
| 700 | 1 | |a Borgen, Molly Destro |e verfasserin |4 aut | |
| 700 | 1 | |a Hanson, Sara N. |e verfasserin |4 aut | |
| 700 | 1 | |a Heyliger, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Larsen, Jennifer J. |e verfasserin |4 aut | |
| 700 | 1 | |a Lenehan, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Orenstein, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Puranik, Arjun |e verfasserin |4 aut | |
| 700 | 1 | |a Speicher, Leigh L. |e verfasserin |4 aut | |
| 700 | 1 | |a Tulledge-Scheitel, Sidna M. |e verfasserin |4 aut | |
| 700 | 1 | |a Venkatakrishnan, AJ |e verfasserin |4 aut | |
| 700 | 1 | |a Wilker, Caroline G. |e verfasserin |4 aut | |
| 700 | 1 | |a Badley, Andrew D. |e verfasserin |4 aut | |
| 700 | 1 | |a Razonable, Raymund R. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 28. Dez. |
| 773 | 1 | 8 | |g year:2022 |g day:28 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.05.23.21257670 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 28 |c 12 | ||